View More View Less
  • 1 Debreceni Egyetem, Orvos- és Egészségtudományi Centrum Belgyógyászati Intézet, Klinikai Immunológia Tanszék Debrecen Móricz Zsigmond körút 22. 4032
  • 2 Debreceni Egyetem, Orvos- és Egészségtudományi Centrum Kardiológiai Klinika Debrecen
  • 3 Debreceni Egyetem, Orvos- és Egészségtudományi Centrum Onkológiai Tanszék Debrecen
Restricted access

Purchase article

USD  $25.00

1 year subscription (Individual Only)

USD  $1,070.00

Az idiopathiás inflammatorikus myopathiák szisztémás, a proximalis végtagizmok progresszív, szimmetrikus gyengeségével jellemezhető immunmediált betegségek. A szerzők áttekintést adnak a gyulladásos izombetegségek esetén alkalmazott biológiai terápiáról. Külön figyelmet fordítanak a B- és T-sejt-gátló terápia legújabb eredményeire. Rávilágítanak az új tanulmányok fontosságára ezen betegségekben. Mindez elvezethet új terápiás lehetőségek bevezetéséhez is. Orv. Hetil., 2014, 155(1), 3–10.

  • Tulassay, Z. (ed.): Fundamentals of internal medicine. [A belgyógyászat alapjai.] Medicina Könyvkiadó, Budapest, 2007. [Hungarian]

    '', in Fundamentals of internal medicine. [A belgyógyászat alapjai.] , (2007 ) -.

  • Bohan, A., Peter, J. B.: Polymyositis and dermatomyositis (first of two parts). N. Engl. J. Med., 1975, 292, 344–347.

    Peter J. B. , 'Polymyositis and dermatomyositis (first of two parts) ' (1975 ) 292 N. Engl. J. Med. : 344 -347.

    • Search Google Scholar
  • Vincze, M., Bodoki, L., Griger, Z., et al.: Myositis – classification of inflammatory muscle diseases. [Myositis – gyulladásos izombetegségek klasszifikálása.] Magyar Reumatológia, 2012, 53, 229–241. [Hungarian]

    Griger Z. , 'Myositis – classification of inflammatory muscle diseases. [Myositis – gyulladásos izombetegségek klasszifikálása.] ' (2012 ) 53 Magyar Reumatológia : 229 -241.

    • Search Google Scholar
  • Aggarwal, R., Oddis, C. V.: Therapeutic advances in myositis. Curr. Opin. Rheumatol., 2012, 24, 635–641.

    Oddis C. V. , 'Therapeutic advances in myositis ' (2012 ) 24 Curr. Opin. Rheumatol. : 635 -641.

    • Search Google Scholar
  • Anić, B., Cerovec, M.: Polymyositis/dermatomyositis – clinical picture and treatment. Reumatizam, 2012, 59, 44–50. [Croatian]

    Cerovec M. , 'Polymyositis/dermatomyositis – clinical picture and treatment ' (2012 ) 59 Reumatizam : 44 -50.

    • Search Google Scholar
  • Lang, B. A., Laxer, R. M., Murphy, G., et al.: Treatment of dermatomyositis with intravenous gammaglobulin. Am. J. Med., 1991, 91, 169–172.

    Murphy G. , 'Treatment of dermatomyositis with intravenous gammaglobulin ' (1991 ) 91 Am. J. Med. : 169 -172.

    • Search Google Scholar
  • Dalakas, M. C., Sonies, B., Dambrosia, J., et al.: Treatment of inclusion-body myositis with IVIg: a double-blind, placebo controlled study. Neurology, 1997, 48, 712–716.

    Dambrosia J. , 'Treatment of inclusion-body myositis with IVIg: a double-blind, placebo controlled study ' (1997 ) 48 Neurology : 712 -716.

    • Search Google Scholar
  • Walter, M. C., Lochmüller, H., Toepfer, M., et al.: High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study. J. Neurol., 2000, 247, 22–28.

    Toepfer M. , 'High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study ' (2000 ) 247 J. Neurol. : 22 -28.

    • Search Google Scholar
  • Danieli, M. G., Pettinari, L., Moretti, R., et al.: Subcutaneous immunoglobulin in polymyositis and dermatomyositis: a novel application. Autoimmun. Rev., 2011, 10, 144–149.

    Moretti R. , 'Subcutaneous immunoglobulin in polymyositis and dermatomyositis: a novel application ' (2011 ) 10 Autoimmun. Rev. : 144 -149.

    • Search Google Scholar
  • Dalakas, M. C.: Inflammatory myopathies: management of steroid resistance. Curr. Opin. Neurol., 2011, 24, 457–462.

    Dalakas M. C. , 'Inflammatory myopathies: management of steroid resistance ' (2011 ) 24 Curr. Opin. Neurol. : 457 -462.

    • Search Google Scholar
  • Dalakas, M. C.: B cells as a therapeutic targets in autoimmune neurological disorders. Nat. Clin. Pract. Neurol., 2008, 4, 557–567.

    Dalakas M. C. , 'B cells as a therapeutic targets in autoimmune neurological disorders ' (2008 ) 4 Nat. Clin. Pract. Neurol. : 557 -567.

    • Search Google Scholar
  • Brodszky, V., Czirják, L., Géher, P., et al.: Rituximab in patients with rheumatoid arthritis: systematic review. [A rituximab szerepe a rheumatoid arthritis kezelésében: irodalmi áttekintés.] Orv. Hetil., 2007, 148, 1883–1893. [Hungarian]

    Géher P. , 'Rituximab in patients with rheumatoid arthritis: systematic review. [A rituximab szerepe a rheumatoid arthritis kezelésében: irodalmi áttekintés.] ' (2007 ) 148 Orv. Hetil. : 1883 -1893.

    • Search Google Scholar
  • Bodoki, L., Vincze, M., Griger, Z., et al.: Efficacy of rituximab treatment in juvenile dermatomyositis. [Rituximab-kezelés hatásossága juvenilis dermatomyositisben.] Magyar Reumatológia, 2013, 54, 107–111. [Hungarian]

    Griger Z. , 'Efficacy of rituximab treatment in juvenile dermatomyositis. [Rituximab-kezelés hatásossága juvenilis dermatomyositisben.] ' (2013 ) 54 Magyar Reumatológia : 107 -111.

    • Search Google Scholar
  • Nistala, K., Wedderburn, L. R.: Update in juvenile myositis. Curr. Opin. Rheumatol., 2013, 25, 742–746.

    Wedderburn L. R. , 'Update in juvenile myositis ' (2013 ) 25 Curr. Opin. Rheumatol. : 742 -746.

    • Search Google Scholar
  • Muñoz-Beamud, F., Isenberg, D. A.: Rituximab as an effective alternative therapy in refractory idiopathic inflammatory myopathies. Clin. Exp. Rheumatol., 2013 Sep 18. [Epub ahead of print]

  • Betteridge, Z. E., Gunawardena, H., McHugh, N. J.: Novel autoantibodies and clinical phenotypes in adult and juvenile myositis. Arthritis Res. Ther., 2011, 13, 209.

    McHugh N. J. , 'Novel autoantibodies and clinical phenotypes in adult and juvenile myositis ' (2011 ) 13 Arthritis Res. Ther. : 209 -.

    • Search Google Scholar
  • Clottu, A., Laffitte, E., Prins, C., et al.: Response of mucocutaneous lesions to rituximab in a case of melanoma differentiation antigen 5-related dermatomyositis. Dermatology, 2012, 225, 376–380.

    Prins C. , 'Response of mucocutaneous lesions to rituximab in a case of melanoma differentiation antigen 5-related dermatomyositis ' (2012 ) 225 Dermatology : 376 -380.

    • Search Google Scholar
  • Mimori, T., Nakashima, R., Hosono, Y.: Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment. Curr. Rheumatol. Rep., 2012, 14, 264–274.

    Hosono Y. , 'Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment ' (2012 ) 14 Curr. Rheumatol. Rep. : 264 -274.

    • Search Google Scholar
  • Luca, N. J., Atkinson, A., Hawkins, C., et al.: Anti-signal recognition particle-positive juvenile polymyositis successfully treated with rituximab. J. Rheumatol., 2012, 39, 1483–1485.

    Hawkins C. , 'Anti-signal recognition particle-positive juvenile polymyositis successfully treated with rituximab ' (2012 ) 39 J. Rheumatol. : 1483 -1485.

    • Search Google Scholar
  • Limaye, V., Hissaria, P., Liew, C. L., et al.: Efficacy of rituximab in refractory antisynthetase syndrome. Intern. Med. J., 2012, 42, e4–e7.

    Liew C. L. , 'Efficacy of rituximab in refractory antisynthetase syndrome ' (2012 ) 42 Intern. Med. J. : e4 -e7.

    • Search Google Scholar
  • Marie, I., Dominique, S., Janvresse, A., et al.: Rituximab therapy for refractory interstitial lung disease related to antisynthetase syndrome. Respir. Med., 2012, 106, 581–587.

    Janvresse A. , 'Rituximab therapy for refractory interstitial lung disease related to antisynthetase syndrome ' (2012 ) 106 Respir. Med. : 581 -587.

    • Search Google Scholar
  • Dézsi, L., Danielsson, O., Gáti, I., et al.: Inclusion body myositis – a rarely recognized disorder. [Zárványtestes myositis – egy ritkán felismert betegség.] Ideggyógyászati Szemle, 2013, 66, 89–101. [Hungarian]

    Gáti I. , 'Inclusion body myositis – a rarely recognized disorder. [Zárványtestes myositis – egy ritkán felismert betegség.] ' (2013 ) 66 Ideggyógyászati Szemle : 89 -101.

    • Search Google Scholar
  • Dalakas, M. C., Rakocevic, G., Schmidt, J., et al.: Effect of alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain, 2009, 132 (Pt 6), 1536–1544.

    Schmidt J. , 'Effect of alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis ' (2009 ) 132 Brain : 1536 -1544.

    • Search Google Scholar
  • Suzuki, N., Aoki, M.: Inclusion body myositis. Brain Nerve, 2011, 63, 1205–1215. [Japanese]

    Aoki M. , 'Inclusion body myositis ' (2011 ) 63 Brain Nerve : 1205 -1215.

  • Mann, H. F., Vencovský, J.: Clinical trials roundup in idiopathic inflammatory myopathies. Curr. Opin. Rheumatol., 2011, 23, 605–611.

    Vencovský J. , 'Clinical trials roundup in idiopathic inflammatory myopathies ' (2011 ) 23 Curr. Opin. Rheumatol. : 605 -611.

    • Search Google Scholar
  • Thompson, B., Corris, P., Miller, J. A., et al.: Alemtuzumab (Campath-1H) for treatment of refractory polymyositis. J. Rheumatol., 2008, 35, 2080–2082.

    Miller J. A. , 'Alemtuzumab (Campath-1H) for treatment of refractory polymyositis ' (2008 ) 35 J. Rheumatol. : 2080 -2082.

    • Search Google Scholar
  • Aranha, A. A., Amer, S., Reda, E. S., et al.: Autoimmune thyroid disease in the use of alemtuzumab for multiple sclerosis: a review. Endocr. Pract., 2013, 19, 821–828.

    Reda E. S. , 'Autoimmune thyroid disease in the use of alemtuzumab for multiple sclerosis: a review ' (2013 ) 19 Endocr. Pract. : 821 -828.

    • Search Google Scholar
  • Dedrick, R. L., Walicke, P., Garovoy, M.: Anti-adhesion antibodies: efalizumab, a humanized anti-CD11a monoclonal antibody. Transpl. Immunol., 2002, 9, 181–186.

    Garovoy M. , 'Anti-adhesion antibodies: efalizumab, a humanized anti-CD11a monoclonal antibody ' (2002 ) 9 Transpl. Immunol. : 181 -186.

    • Search Google Scholar
  • Gauvreau, G. M., Becker, A. B., Boulet, L. P., et al.: The effects of an anti-CD11a mAb, efalizumab, on allergen-induced airway responses and airway inflammation in subjects with atopic asthma. J. Allergy Clin. Immunol., 2003, 112, 331–338.

    Boulet L. P. , 'The effects of an anti-CD11a mAb, efalizumab, on allergen-induced airway responses and airway inflammation in subjects with atopic asthma ' (2003 ) 112 J. Allergy Clin. Immunol. : 331 -338.

    • Search Google Scholar
  • Vincenti, F.: New monoclonal antibodies in renal transplantation. Minerva Urol. Nefrol., 2003, 55, 57–66.

    Vincenti F. , 'New monoclonal antibodies in renal transplantation ' (2003 ) 55 Minerva Urol. Nefrol. : 57 -66.

    • Search Google Scholar
  • Huber, A., Gaffal, E., Bieber, T., et al.: Treatment of recalcitrant dermatomyositis with efalizumab. Acta Derm. Venereol., 2006, 86, 254–255.

    Bieber T. , 'Treatment of recalcitrant dermatomyositis with efalizumab ' (2006 ) 86 Acta Derm. Venereol. : 254 -255.

    • Search Google Scholar
  • Hillmen, P., Young, N. S., Schubert, J., et al.: The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N. Engl. J. Med., 2006, 355, 1233–1243.

    Schubert J. , 'The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria ' (2006 ) 355 N. Engl. J. Med. : 1233 -1243.

    • Search Google Scholar
  • Kazuki, T., Bookbinder, S., Furie, R.: A pilot study of eculizumab in patients with dermatomyositis. Arthritis Res., 2002, 46, S489.

    Furie R. , 'A pilot study of eculizumab in patients with dermatomyositis ' (2002 ) 46 Arthritis Res. : S489 -.

    • Search Google Scholar
  • Efthimiou, P., Schwartzman, S., Kagen, L. J.: Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients. Ann. Rheum. Dis., 2006, 65, 1233–1236.

    Kagen L. J. , 'Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients ' (2006 ) 65 Ann. Rheum. Dis. : 1233 -1236.

    • Search Google Scholar
  • Riley, P., McCann, L. J., Maillard, S. M., et al.: Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. Rheumatology (Oxford), 2008, 47, 877–880.

    Maillard S. M. , 'Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis ' (2008 ) 47 Rheumatology (Oxford) : 877 -880.

    • Search Google Scholar
  • Iannone, F., Scioscia, C., Falappone, P. C., et al.: Use of etanercept in the treatment of dermatomyositis: a case series. J. Rheumatol., 2006, 33, 1802–1804.

    Falappone P. C. , 'Use of etanercept in the treatment of dermatomyositis: a case series ' (2006 ) 33 J. Rheumatol. : 1802 -1804.

    • Search Google Scholar
  • Dastmalchi, M., Grundtman, C., Alexanderson, H., et al.: A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann. Rheum. Dis., 2008, 67, 1670–1677.

    Alexanderson H. , 'A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies ' (2008 ) 67 Ann. Rheum. Dis. : 1670 -1677.

    • Search Google Scholar
  • Hengstman, G. J., De Bleecker, J. L., Feist, E., et al.: Open-label trial of anti-TNF-alpha in dermato- and polymyositis treated concomitantly with methotrexate. Eur. Neurol., 2008, 59, 159–163.

    Feist E. , 'Open-label trial of anti-TNF-alpha in dermato- and polymyositis treated concomitantly with methotrexate ' (2008 ) 59 Eur. Neurol. : 159 -163.

    • Search Google Scholar
  • Vordenbäumen, S., Neuen-Jacob, E., Richter, J., et al.: Inclusion body myositis in a patient with long standing rheumatoid arthritis treated with anti-TNF-alpha and rituximab. Clin. Rheumatol., 2010, 29, 555–558.

    Richter J. , 'Inclusion body myositis in a patient with long standing rheumatoid arthritis treated with anti-TNF-alpha and rituximab ' (2010 ) 29 Clin. Rheumatol. : 555 -558.

    • Search Google Scholar
  • Rouster-Stevens, K. A., Ferguson, L., Morgan, G., et al.: Pilot study of etanercept in patients with refractory juvenile dermatomyositis. Arthritis Care Res. (Hoboken), 2013 Oct 14. [Epub ahead of print]

  • Muscle Study Group: A randomized, pilot trial of etanercept in dermatomyositis. Ann. Neurol., 2011, 70, 427–436.

    'A randomized, pilot trial of etanercept in dermatomyositis ' (2011 ) 70 Ann. Neurol. : 427 -436.

    • Search Google Scholar
  • Kosmidis, M. L., Alexopoulos, H., Tzioufas, A. G., et al.: The effect of anakinra, an IL1 receptor antagonist, in patients with sporadic inclusion body myositis (sIBM): A small pilot study. J. Neurol. Sci., 2013, 334, 123–125.

    Tzioufas A. G. , 'The effect of anakinra, an IL1 receptor antagonist, in patients with sporadic inclusion body myositis (sIBM): A small pilot study ' (2013 ) 334 J. Neurol. Sci. : 123 -125.

    • Search Google Scholar
  • Estublier, C., Stankovic Stojanovic, K., Bergerot, J. F., et al.: Myositis in a patient with familial Mediterranean fever and spondyloarthritis successfully treated with anakinra. Joint Bone Spine, 2013, 80, 645–649.

    Bergerot J. F. , 'Myositis in a patient with familial Mediterranean fever and spondyloarthritis successfully treated with anakinra ' (2013 ) 80 Joint Bone Spine : 645 -649.

    • Search Google Scholar
  • Prieur, A. M., Dayer, A., Roux-Lombard, P., et al.: Levels of cytokine inhibitors: a possible marker of disease activity in childhood dermatomyositis and polymyositis. Clin. Exp. Rheumatol., 1997, 15, 211–214.

    Roux-Lombard P. , 'Levels of cytokine inhibitors: a possible marker of disease activity in childhood dermatomyositis and polymyositis ' (1997 ) 15 Clin. Exp. Rheumatol. : 211 -214.

    • Search Google Scholar
  • Son, K., Tomita, Y., Shimizu, T., et al.: Abnormal IL-1 receptor antagonist production in patients with polymyositis and dermatomyositis. Intern. Med., 2000, 39, 128–135.

    Shimizu T. , 'Abnormal IL-1 receptor antagonist production in patients with polymyositis and dermatomyositis ' (2000 ) 39 Intern. Med. : 128 -135.

    • Search Google Scholar
  • Grundtman, C., Salomonsson, S., Dorph, C., et al.: Immunolocalization of interleukin-1 receptors in the sarcolemma and nuclei of skeletal muscle in patients with idiopathic inflammatory myopathies. Arthritis Rheum., 2007, 56, 674–687.

    Dorph C. , 'Immunolocalization of interleukin-1 receptors in the sarcolemma and nuclei of skeletal muscle in patients with idiopathic inflammatory myopathies ' (2007 ) 56 Arthritis Rheum. : 674 -687.

    • Search Google Scholar
  • Zong, M., Dorph, C., Dastmalchi, M., et al.: Anakinra treatment in patients with refractory inflammatory myopathies and possible predictive response biomarkers: a mechanistic study with 12 months follow-up. Ann. Rheum. Dis., 2013 Apr 26. [Epub ahead of print]

  • Furlan, A., Botsios, C., Ruffatti, A., et al.: Antisynthetase syndrome with refractory polyarthritis and fever successfully treated with the IL-1 receptor antagonist, anakinra: A case report. Joint Bone Spine, 2008, 75, 366–367.

    Ruffatti A. , 'Antisynthetase syndrome with refractory polyarthritis and fever successfully treated with the IL-1 receptor antagonist, anakinra: A case report ' (2008 ) 75 Joint Bone Spine : 366 -367.

    • Search Google Scholar
  • Narazaki, M., Hagihara, K., Shima, Y., et al.: Therapeutic effect of tocilizumab on two patients with polymyositis. Rheumatology (Oxford), 2011, 50, 1344–1346.

    Shima Y. , 'Therapeutic effect of tocilizumab on two patients with polymyositis ' (2011 ) 50 Rheumatology (Oxford) : 1344 -1346.

    • Search Google Scholar

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Nov 2020 13 8 3
Dec 2020 27 0 0
Jan 2021 6 0 0
Feb 2021 6 0 0
Mar 2021 8 1 1
Apr 2021 3 0 0
May 2021 0 0 0